Survival analysis, more than meets the eye
| العنوان: | Survival analysis, more than meets the eye |
|---|---|
| المؤلفون: | Marko Skelin, Tomo Lucijanić, Marko Lucijanic |
| المصدر: | Biochemia Medica Volume 27 Issue 1 |
| بيانات النشر: | Medicinska naklada, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | medicine.medical_specialty, Lessons in Biostatistics, Clinical Biochemistry, Context (language use), 030204 cardiovascular system & hematology, law.invention, Efficacy, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Statistical significance, Medicine, Humans, Medical physics, p-value, statistics, clinical trial, survival analysis, primary myelofibrosis, software, Randomized Controlled Trials as Topic, Models, Statistical, business.industry, Biochemistry (medical), food and beverages, Prognosis, Survival Analysis, Surgery, Test (assessment), Log-rank test, Clinical trial, Clinical Trials, Phase III as Topic, Primary Myelofibrosis, 030220 oncology & carcinogenesis, business |
| الوصف: | The log-rank test is a cornerstone of phase III oncology clinical trials. However, there are at least three different mathematical procedures that can be named the log-rank test and two of them are widely used by commercial statistical programs. Consequently, different P values can be obtained. In the case of a borderline statistical significance, this can mean the difference between the evidence (significant P value) and merely an observation. Since all three methods can be reported under the same name, space for possible data manipulation occurs. This should be of a particular concern in a drug regulatory context. Randomized clinical trials with borderline significant results should perhaps be required to report P values calculated by all three methods, in order to properly evaluate drug efficacy. An interactive MS Excel spreadsheet that uses all three logrank test variants is prepared as a supplementary file accompanying this article. Association of high grade of bone marrow fibrosis with poor outcome in patients with myelofibrosis is used as an example. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1846-7482 1330-0962 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2073584c4c604ed22b54330f8a4a655bTest https://hrcak.srce.hr/file/259750Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2073584c4c604ed22b54330f8a4a655b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18467482 13300962 |
|---|